Related references
Note: Only part of the references are listed.Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
Christopher J. Duff et al.
BIOCHEMICAL JOURNAL (2009)
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
Robert J. Schmidt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
Gilles Lambert et al.
CLINICAL CHEMISTRY (2008)
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9
Sanae Kourimate et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2008)
Cross-talk between statins and PPAR alpha in cardiovascular diseases: Clinical evidence and basic mechanisms
Rejane Paumelle et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2008)
Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Guoqing Cao et al.
Endocrine Metabolic & Immune Disorders-Drug Targets (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
Michel Farnier
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol
William E. Alborn et al.
CLINICAL CHEMISTRY (2007)
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li et al.
BIOCHEMICAL JOURNAL (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Yue-Wei Qian et al.
JOURNAL OF LIPID RESEARCH (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia -: Two randomized controlled trials
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol
Tommaso Fasano et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Fenofibrate - A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus
Gillian M. Keating et al.
DRUGS (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia
KN Maxwell et al.
CURRENT OPINION IN LIPIDOLOGY (2005)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Share Paper
